A Phase 1b-2, Open-Label, Dose-Escalation, Expansion and Optimization Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of LRK-4189 Alone and in Combination With mFOLFOX6 or FOLFIRI in Patients With Solid Tumors
The goal of this clinical trial is to learn if investigational agent LRK-4189 works to treat solid tumors in adults, with a focus on colorectal cancer. It will also learn about the safety of drug LRK-4189. The main questions it aims to answer are: Is LRK-4189, administered alone or in combination with standard chemotherapy regimens, safe and tolerable in patients with solid tumors? Participants will: * Take investigational agent LRK-4189 alone or in combination with standard chemotherapy regimens every day for up to 3 years. * Visit the clinic once every week for checkups and tests.
• Willing and able to sign the study consent form and take part in all required study visits, tests, and procedures.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
• Have a locally advanced or metastatic cancer that cannot be removed with surgery and has gotten worse despite treatment.
• Cancer can be measured on scans, such as CT or MRI.
• Willing to have tumor biopsies, meaning small samples of your tumor will be collected during the study.
• Heart rhythm test (ECG) shows a normal result within safe limits.
• Blood test results at screening are within an acceptable and stable range.
• If you are a woman, you are not able to become pregnant, or you agree not to become pregnant during the study and to use approved birth control methods.
• If you are a man, you agree not to donate sperm during the study. If you have sex with a partner who could become pregnant, you agree to use approved birth control methods during the study.